Hbm Healthcare Investments Ag

HBM Healthcare Investments AG is listed on the SIX Swiss Exchange, so shareholder disclosure follows Switzerland’s financial markets infrastructure rules: only investors whose holdings cross a reporting threshold, starting at 3% of voting rights, must notify the company and the SIX Disclosure Office. Available information is therefore limited to major shareholders rather than a complete shareholder register.

Per notifications referenced on the company’s own investor relations pages, two shareholder groups have disclosed holdings above the reporting threshold: Nogra Group entities registered in Luxembourg — comprising Nogra Pharma Invest S.à r.l., GG 1978 SICAF-SIF S.A. and MGG Strategic SICAF-SIF S.A. — reported within the 15%-20% disclosure band, and Saba Capital Management, L.P., a US-based investment manager, reported within the 10%-15% band. Because Swiss disclosure notifications report the threshold band crossed rather than an exact daily percentage, these figures represent the band at the time of the relevant notification rather than a current live stake.

No individual ultimate beneficial owner can be verified from the available notifications: both disclosed major shareholders are themselves corporate or fund vehicles, and no filing identifies a natural person controlling either one.

Data availability: Major shareholders only. The Zug commercial register does not separately list shareholders, and no complete shareholder register is publicly available for a SIX-listed company of this kind; only holdings that cross the statutory disclosure thresholds are published. The on-file shareholder data for this profile lists index-tracking fund positions (for example, Invesco Global Listed Private Equity ETF and ALPS/Red Rocks Listed Private Equity Portfolio), which reflect passive index inclusion rather than the statutory major-shareholder disclosures described above and do not appear in the SIX disclosure register referenced by the company.

HBM Healthcare Investments AG’s board of directors (Verwaltungsrat), as listed on the company’s own website, has five members: Hans Peter Hasler (Chairman), Mario G. Giuliani, Dr Elaine V. Jones, Dr Rudolf Lanz and Dr Stella Xu. The company’s Chief Financial Officer, Erwin Troxler, a Swiss Certified Public Accountant, has held the CFO role since 2011 and has worked at HBM since 2005, according to the company’s shareholder-meeting materials.

The Zug commercial register data on file for this profile lists only one of these five board members (recorded as “Elaine Verne Jones,” Mitglied des Verwaltungsrates) together with the CFO and two further individuals holding the registered signatory titles “Investment Advisor” (Alexander G. Asam) and “Investment Professional” (Thomas Thaler); it does not include Hans Peter Hasler, Mario G. Giuliani, Dr Rudolf Lanz or Dr Stella Xu. This profile therefore reflects a partial view of the current board rather than its full composition.

No appointment or resignation dates are available in the on-file registry data for any of these individuals, and no source identifies the nationality of any officer; nationality should be treated as not disclosed for all listed individuals rather than inferred from name or address.

Data availability: Partial. The Zug commercial register does not consistently publish appointment dates, and the on-file officer data does not reflect the full five-member board reported on the company’s own website as of the current review.

HBM Healthcare Investments AG is a publicly listed investment company with no identified controlling parent; its own major disclosed shareholders (see Shareholders) are financial investors rather than corporate parents. The company’s registered subsidiary is HBM Healthcare Investments (Cayman) Ltd. (Cayman Islands, registration KY 110122), which serves as the investment-holding vehicle through which the group’s portfolio positions are held.

Because HBM Healthcare Investments AG qualifies as an investment entity under IFRS 10, this Cayman subsidiary — like the group’s other portfolio holdings — is not consolidated into the company’s financial statements; it is instead measured at fair value through profit or loss, consistent with the investment-entity exception under IFRS 10. Entities appearing beneath the Cayman subsidiary in the on-file corporate-linkage data, including Farmalatam Holding Inc. (Panama), Farmalatam Colombia SAS (recorded as in liquidation), Farmatalam de Mexico, S. de R.L. de C.V. and HBM Private Equity India (Mauritius), represent underlying portfolio investments rather than consolidated operating subsidiaries, consistent with the treatment the company’s own annual report describes for HBM Private Equity India.

Data availability: Partial. The immediate subsidiary relationship with the Cayman entity is corroborated by external corporate-registration sources, but the deeper portfolio holdings should be read as investment positions rather than a conventional consolidated group structure.